Free tool
Rare disease stocks
We cover 28 companies grouped under the Rare disease theme. The median market value in the group is $2.74B. Across the group, the median move over the past trading day is +0.12%. 58% of the 24 with a 200-day average trade above it. Price change over the past year runs from −36.5% to +259.3% across the middle 80 percent of the group, with a median of +22.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
28 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| VX1.DE | Vertex Pharmaceuticals Incorporated | 475.00 EUR | +10.21% | +23.55% | +41.64% | Nov 2, 2026 |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $549.02 | +0.13% | +22.11% | +40.77% | Nov 2, 2026 |
| 0HD2.L | Alnylam Pharmaceuticals, Inc. | $241.82 | +0.67% | −39.23% | −46.60% | Oct 29, 2026 |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | 204.00 EUR | −19.59% | −40.19% | −10.21% | Oct 29, 2026 |
| 0JAV.L | Insmed Incorporated | $125.00 | +0.43% | −28.28% | −7.52% | Oct 29, 2026 |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | 52.70 EUR | +2.53% | +10.68% | +1.80% | Nov 10, 2026 |
| ABVX.PA | ABIVAX Société Anonyme | 102.30 EUR | −5.63% | −11.04% | +48.91% | Sep 21, 2026 |
| 0HNC.L | BioMarin Pharmaceutical Inc. | $66.19 | +0.05% | +11.54% | +15.03% | Oct 26, 2026 |
| CAMX.ST | Camurus AB (publ) | 615.00 SEK | −1.68% | +0.49% | −15.35% | Nov 5, 2026 |
| 0L35.L | Sarepta Therapeutics, Inc. | $18.51 | +1.60% | −13.25% | −0.06% | Nov 4, 2026 |
| 0LIF.L | Ultragenyx Pharmaceutical Inc. | $26.19 | +1.39% | +12.52% | −13.39% | Nov 3, 2026 |
| 0HB0.L | Agios Pharmaceuticals, Inc. | $34.05 | +0.18% | +26.06% | −13.00% | Oct 29, 2026 |
| DBV.PA | DBV Technologies S.A. | 2.53 EUR | +5.42% | −22.51% | +60.13% | Oct 28, 2026 |
| GNFT.PA | Genfit S.A. | 14.30 EUR | +5.30% | +172.38% | +310.45% | Sep 29, 2026 |
| 0KBU.L | Omeros Corporation | $18.44 | −4.75% | +11.14% | +332.86% | Nov 12, 2026 |
| XUP.DE | Genfit S.A. | 14.08 EUR | −1.81% | +164.41% | +166.82% | Sep 29, 2026 |
| 0AB6.L | Hyloris Pharmaceuticals SA | 4.38 EUR | −1.79% | −38.83% | −33.23% | Sep 24, 2026 |
| 0H8T.L | Aclaris Therapeutics, Inc. | $6.14 | −6.69% | +105.92% | +237.38% | Nov 5, 2026 |
| 0A43.L | Inovio Pharmaceuticals, Inc. | $1.32 | +4.35% | −20.55% | −44.09% | Nov 10, 2026 |
| 0A8E.L | Xeris Biopharma Holdings, Inc. | $8.78 | +0.57% | +20.42% | +10.86% | Nov 5, 2026 |
| 0A9G.L | Mereo BioPharma Group plc | $0.28 | −2.36% | −42.56% | −84.25% | Nov 9, 2026 |
| 0ABW.L | Egetis Therapeutics AB (publ) | 8.08 SEK | +8.09% | +63.15% | +58.43% | Nov 6, 2026 |
| 0K1R.L | Viridian Therapeutics, Inc. | $24.40 | +1.29% | −21.12% | +30.27% | Nov 5, 2026 |
| 0L49.L | SCYNEXIS, Inc. | $5.95 | +15.50% | +858.64% | +604.63% | Nov 4, 2026 |
| 0UNL.L | Nektar Therapeutics | $74.20 | +6.73% | +14.04% | +14.04% | Nov 12, 2026 |
| 1AE.DE | argenx SE | 898.60 EUR | +15.89% | +24.05% | +38.37% | Oct 22, 2026 |
| 2X1.DE | ABIVAX Société Anonyme | 100.50 EUR | −6.77% | −12.30% | +33.82% | Sep 21, 2026 |
| DBV.DE | DBV Technologies S.A. | 2.46 EUR | +12.83% | −25.17% | +64.35% | Oct 28, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.